type 1 diabetes

type 1 diabetes
IntDiabetesFed · Public domain · source
Name	Type 1 diabetes
Field	Endocrinology, Immunology
Symptoms	Polyuria, polydipsia, weight loss, fatigue
Complications	Diabetic ketoacidosis, cardiovascular disease, nephropathy, retinopathy, neuropathy
Onset	Often childhood or adolescence
Causes	Autoimmune destruction of pancreatic beta cells
Diagnosis	Elevated plasma glucose, low C-peptide, presence of autoantibodies
Treatment	Insulin therapy, glucose monitoring, lifestyle measures

type 1 diabetes

Type 1 diabetes is a chronic autoimmune endocrinopathy characterized by destruction of pancreatic beta cells leading to absolute insulin deficiency. It commonly presents in childhood or adolescence but can occur at any age and requires lifelong insulin replacement and multispecialty care. Management aims to maintain glycemic control to prevent acute metabolic crises and long-term vascular complications.

Signs and symptoms

Classic presenting features include polyuria, polydipsia, nocturia and unexplained weight loss; affected individuals may also report fatigue, blurred vision and recurrent infections. In many cases presentation is acute with symptoms progressing to dehydration, altered consciousness or Diabetic ketoacidosis requiring emergency care; providers from American Diabetes Association, Royal College of Physicians, World Health Organization and pediatric centers often recognize these red flags. Physical findings may include tachycardia, hypotension or Kussmaul respiration in severe metabolic decompensation; specialists in Pediatrics, Endocrinology and Intensive Care Medicine coordinate stabilization. Chronic poorly controlled disease can manifest as microvascular and macrovascular complications noted by teams at institutions such as Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic and Charité – Universitätsmedizin Berlin.

Cause and pathophysiology

Pathogenesis is principally autoimmune: genetically susceptible individuals exposed to environmental triggers develop T cell–mediated destruction of pancreatic beta cells within the islets of Langerhans. Genetic associations include polymorphisms in the HLA region, particularly HLA-DR and HLA-DQ alleles identified in studies by groups at Harvard Medical School, University of Oxford, Karolinska Institutet and University of Cambridge. Environmental factors investigated by researchers at Centers for Disease Control and Prevention, European Prospective Investigation into Cancer and Nutrition, Karolinska Institutet and UCSF include viral infections (for example Enteroviruses), early-life exposures, and microbiome alterations described by teams at Broad Institute and Scripps Research. Autoantibodies—against insulin, glutamic acid decarboxylase (GAD65), insulinoma-associated antigen-2 (IA-2) and zinc transporter 8 (ZnT8)—are markers studied at University of Florida, Barbara Davis Center, Imperial College London and University of Colorado for prediction and staging. The biochemical consequence is inadequate insulin-mediated glucose uptake, unopposed glucagon action and increased lipolysis leading to ketogenesis, a mechanism elaborated in textbooks from Oxford University Press and Elsevier.

Diagnosis

Diagnostic criteria follow consensus statements from American Diabetes Association, World Health Organization and regional endocrine societies; measurements include fasting plasma glucose, 2-hour plasma glucose after oral glucose tolerance testing, and glycated hemoglobin (HbA1c). Distinguishing insulin deficiency from insulin resistance involves assessment of C-peptide levels and islet autoantibody testing performed by laboratories affiliated with Mayo Clinic, Eli Lilly and Company research groups, Novo Nordisk clinical networks and university hospitals. Acute presentations with hyperglycemia and metabolic acidosis require arterial blood gases and electrolyte assessment in settings such as Massachusetts General Hospital emergency departments and Johns Hopkins Hospital intensive care units. Differential diagnosis includes monogenic diabetes forms identified by genetic testing centers at Wellcome Trust Sanger Institute, NIH and university genetics services.

Management and treatment

Lifelong insulin replacement is the cornerstone, delivered via multiple daily injections or continuous subcutaneous insulin infusion (insulin pump therapy) offered by specialist centers including St Thomas' Hospital, Great Ormond Street Hospital, Children's Hospital of Philadelphia and tertiary endocrine clinics. Adjunctive technologies include continuous glucose monitoring developed by companies such as Dexcom, Medtronic, Abbott Laboratories and hybrid closed-loop systems evaluated in trials at University of Cambridge, Stanford University and University of Washington. Acute management of diabetic ketoacidosis requires fluid resuscitation, intravenous insulin and electrolyte repletion per protocols from American Diabetes Association and British Society for Paediatric Endocrinology and Diabetes. Education, psychosocial support and multidisciplinary care involve teams from Diabetes UK, JDRF (Juvenile Diabetes Research Foundation), American Association of Clinical Endocrinologists and community clinics. Adjunct pharmacotherapies and immunomodulatory trials have been conducted at NIDDK, National Institute for Health and Care Research and academic centers including Yale University and University of Oxford.

Complications and prognosis

Short-term complications include hypoglycemia and diabetic ketoacidosis; long-term complications encompass microvascular disease (retinopathy, nephropathy, neuropathy) and macrovascular disease (coronary artery disease, stroke) monitored by ophthalmology, nephrology and cardiology services at Bascom Palmer Eye Institute, Mayo Clinic, Royal Infirmary of Edinburgh and Mount Sinai Hospital. Prognosis has improved with advances in insulin formulations from Eli Lilly and Company and Novo Nordisk, glucose-sensing technology from Dexcom and Abbott, and integrated care pathways developed by NHS England, CDC programs and academic centers. Landmark cohort studies such as the DCCT and EDIC have demonstrated that early tight glycemic control reduces long-term complications, findings reinforced by follow-up research at University of Pittsburgh, University of Toronto and Karolinska Institutet.

Epidemiology and risk factors

Incidence and prevalence vary geographically: higher rates reported in Scandinavian countries (data from Sweden, Finland and registries at Karolinska Institutet), increasing incidence in many regions documented by WHO and IDF (International Diabetes Federation). Risk factors include HLA genotypes, family history studied at Framingham Heart Study infrastructure, certain neonatal and viral exposures examined by teams at CDC and European Centre for Disease Prevention and Control, and possible associations with dietary factors investigated by University of Helsinki and Harvard T.H. Chan School of Public Health. Global initiatives by JDRF, WHO and national public health agencies monitor trends and support research into prevention, immunotherapy and beta cell replacement strategies pursued at Harvard Medical School, Stanford University, University of California, San Francisco and biotech companies in Boston and San Francisco Bay Area.

Category:Endocrine diseases